SILCS-RNA: Toward a Structure-Based Drug Design Approach for Targeting RNAs with Small Molecules
- 1 August 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Chemical Theory and Computation
- Vol. 18 (9) , 5672-5691
Abstract
RNA molecules can act as potential drug targets in different diseases, as their dysregulated expression or misfolding can alter various cellular processes. Noncoding RNAs account for ∼70% of the human genome, and these molecules can have complex tertiary structures that present a great opportunity for targeting by small molecules. In the present study, the site identification by ligand competitive saturation (SILCS) computational approach is extended to target RNA, termed SILCS-RNA. Extensions to the method include an enhanced oscillating excess chemical potential protocol for the grand canonical Monte Carlo calculations and individual simulations of the neutral and charged solutes from which the SILCS functional group affinity maps (FragMaps) are calculated for subsequent binding site identification and docking calculations. The method is developed and evaluated against seven RNA targets and their reported small molecule ligands. SILCS-RNA provides a detailed characterization of the functional group affinity pattern in the small molecule binding sites, recapitulating the types of functional groups present in the ligands. The developed method is also shown to be useful for identification of new potential binding sites and identifying ligand moieties that contribute to binding, granular information that can facilitate ligand design. However, limitations in the method are evident including the ability to map the regions of binding sites occupied by ligand phosphate moieties and to fully account for the wide range of conformational heterogeneity in RNA associated with binding of different small molecules, emphasizing inherent challenges associated with applying computer-aided drug design methods to RNA. While limitations are present, the current study indicates how the SILCS-RNA approach may enhance drug discovery efforts targeting RNAs with small molecules.Keywords
Funding Information
- Office of the Director (ACI-1548562)
- National Institute of General Medical Sciences (GM131710)
- University of Maryland Computer Aided Drug Design Center
This publication has 119 references indexed in Scilit:
- Optimization of the CHARMM Additive Force Field for DNA: Improved Treatment of the BI/BII Conformational EquilibriumJournal of Chemical Theory and Computation, 2011
- A Small-Molecule Probe Induces a Conformation in HIV TAR RNA Capable of Binding Drug-Like FragmentsJournal of Molecular Biology, 2011
- Discovery of selective bioactive small molecules by targeting an RNA dynamic ensembleNature Chemical Biology, 2011
- Impact of 2′‐hydroxyl sampling on the conformational properties of RNA: Update of the CHARMM all‐atom additive force field for RNAJournal of Computational Chemistry, 2011
- Reproducing Crystal Binding Modes of Ligand Functional Groups Using Site-Identification by Ligand Competitive Saturation (SILCS) SimulationsJournal of Chemical Information and Modeling, 2011
- CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fieldsJournal of Computational Chemistry, 2009
- Adaptive Ligand Binding by the Purine Riboswitch in the Recognition of Guanine and Adenine AnalogsStructure, 2009
- Docking to RNA via Root-Mean-Square-Deviation-Driven Energy Minimization with Flexible Ligands and Flexible TargetsJournal of Chemical Information and Modeling, 2008
- HCV and CSFV IRES domain II mediate eIF2 release during 80S ribosome assemblyThe EMBO Journal, 2007
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004